Overview

• U.S. medical technologies firm's Q1 revenue from continuing ops rose 32% yr/yr, up 5% pro forma adjusted

• Adjusted EPS from continuing ops fell to $1.39 from $1.44 a year earlier

• Company maintains 2026 revenue growth and adjusted EPS outlook; plans $1 bln buyback, $800 mln debt cut

Outlook

• Teleflex maintains 2026 GAAP revenue growth guidance of 14.4% to 15.4%

• Company maintains 2026 pro forma adjusted constant currency revenue growth outlook of 4.5% to 5.5%

• Teleflex maintains 2026 adjusted diluted EPS guidance of $6.25 to $6.55

Result Drivers

• PORTFOLIO CHANGES - Revenue growth reflects impact of strategic divestitures and acquisition of Vascular Intervention business

• RESTRUCTURING & INTEGRATION COSTS - Higher restructuring, integration, and amortization expenses weighed on adjusted EPS

• TRANSFORMATION PLAN EXECUTION - Co cited disciplined execution and progress on transformation plan as supporting Q1 performance

Company press release: ID:nBw9rwwd1a

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Adjusted EPS continuing operations		$1.39
Q1 EPS continuing operations		-$0.11

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 11 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

• Wall Street's median 12-month price target for Teleflex Inc is $135.00, about 9.6% above its May 6 closing price of $123.23

• The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 7 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.